

Ractopamine, Monensin, and Tylosin Plus Type C Medicated Cattle Feed (carcass leanness)

For Use in Cattle Feeds Only

Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.

INDICATIONS

For increased rate of weight gain, improved feed efficiency, increased carcass leanness, prevention and control of coccidiosis due to *Eimeria bovis* and *E. zuernii* and reduction of incidence of liver abscesses caused by *Fusobacterium necrophorum* and *Arcanobacterium (Actinomyces) pyogenes* in cattle fed in confinement for slaughter for the last 28 to 42 days on feed.

ACTIVE DRUG INGREDIENTS

Ractopamine HCl ¹	9.8 to 24.6 g/ton*
Monensin, USP ²	10 to 40 g/ton*
Tylosin phosphate ³	8 to 10 g/ton*

GUARANTEED ANALYSIS

Crude Protein, not less than.....	_____ %
Non-Protein Nitrogen (NPN) ⁴ , not more than.....	_____ %
Crude Fat, not less than.....	_____ %
Crude Fiber, not more than.....	_____ %
Calcium, not less than.....	_____ %
Calcium, not more than.....	_____ %
Phosphorus, not less than.....	_____ %
Salt ⁵ , not less than.....	_____ %
Salt ⁵ , not more than.....	_____ %
Sodium ⁶ , not less than.....	_____ %
Sodium ⁶ , not more than.....	_____ %
Potassium, not less than.....	_____ %
Vitamin A ^{5,7} , not less than.....	_____ I.U./lb

⁴When added.

⁵If added.

⁶Shall be guaranteed only when total sodium exceeds that furnished by the maximum salt guarantee.

⁷Other than precursors of Vitamin A.

INGREDIENTS

Each ingredient must be named in accordance with the names and definitions adopted by the Association of American Feed Control Officials.

FEEDING DIRECTIONS

Feed continuously as sole ration to provide 90 to 430 mg/hd/day ractopamine and 0.14 to 0.42 mg monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/hd/day and 60 to 90 mg/hd/day tylosin for the last 28 to 42 days on feed.


CAUTIONS

Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Monensin medicated cattle feed is safe for use in cattle only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result. If feed refusals containing monensin are fed to other groups of cattle, the concentration of monensin in the refusals and amount of refusals fed should be taken into consideration to prevent monensin overdosing.


Do not use in any finished feed (supplement, concentrate or complete feed) containing in excess of 2% bentonite.

Ractopamine HCl is not for animals intended for breeding.

WARNINGS



A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal.



The active ingredient in Optaflexx, ractopamine hydrochloride, is a beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Optaflexx 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Optaflexx, use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. The material safety data sheet contains more detailed occupational safety information. To report adverse effects, access medical information, or obtain additional product information, call 1-800-428-4441.

MANUFACTURED BY

BLUE BIRD FEED MILL
Any town, USA 12345

Net Weight lb (kg) on bag or bulk

*The medicated feed label must state a single drug concentration.

¹Sourced from OptaflexxTM, NADA# 141-221

²Sourced from RumensinTM, NADA# 95-735

³Sourced from TylanTM, NADA# 12-491

Elanco, Rumensin, Tylan, Optaflexx, and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.